 WATERTOWN, Mass., Dec. 18, 2020 GLOBE NEWSWIRE -- EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT, a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders, today announced a royalty monetization agreement with SWK Holdings Corporation SWK for royalties payable to EyePoint under its license agreement with Alimera Sciences, Inc. Alimera for ILUVIEN. EyePoint has received a one-time 16.5 million payment from SWK and, in return, SWK is entitled to receive future royalties payable to EyePoint from the Alimera agreement. 